







an Open Access Journal by MDPI

Clinical and Translational Research in Head and Neck Cancer

Guest Editor:

Dr. Young J. Kim

Chair Oncology, Global Development Scientific Council, Regeneron Pharmaceuticals, New York, NY, USA

Deadline for manuscript submissions:

closed (31 January 2024)

Message from the Guest Editor

Dear Colleagues,

Head and neck cancer encompass multiple histologic tumors that can represent the breadth of most human cancer, and their unique occurrences in the face/scalp and the upper digestive tracts to include the sinonasal tracts, oral cavity, oropharynx, larynx, and cervical esophagus provide unique challenges for scientists and clinicians. Although there are now new approved drugs for many of these tumor types, there are still important clinical concerns for weighing oncologic cure and functional preservation. Hence, incorporation of a new modalities, such as immunotherapy and targeted biologics, will require basic, clinical, and translational research for optimal patient care that incorporates locoregional recurrence. overall survival. and aualitv maintenance. This Special Issue presents some of these recent advances in oncologic therapeutics in head and neck cancer patients to promote future translational and clinical studies













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us